NHI to cover NT$49 million gene therapy drug for muscle atrophy

A one-time-only drug to treat spinal muscular atrophy (SMA) that will cost NT$49 million (US$1.58 million) will soon be covered for infants six months old and under by Taiwan's universal health insurance system.

(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)